News & Events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

Invitation to investor meeting 3rd October 2023, 2:00 pm (CET)

20 September 2023

Molecure submits application to the European Medicines Agency (EMA) to initiate a phase II clinical trial in the European Union and Norway to investigate OATD-01 for the treatment of pulmonary sarcoidosis

9 September 2023

The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch

22 July 2023

Molecure completes successful Secondary Public Offering of approximately USD 12 million with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies

19 July 2023

Molecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule OATD-01, taking another important step in the development of this program.

3 July 2023

Molecure Files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA ahead of a planned Phase 2 pulmonary sarcoidosis study

22 June 2023

Events & Presentations

EFMC – International Symposium on Medicinal Chemistry – Ljubljana 02-06.09.2018

17 September 2018

ERS International Congress 2018 – Paris, France 15-19.09.2018

14 September 2018

54th International Conference on Medicinal Chemistry, Strasbourg, France – July 4-6, 2018.

17 July 2018

ATS 2018, 18 – 23 May, San Diego, USA

21 May 2018

ESMO Immuno Oncology Congress Geneva – December 7-10

1 December 2017

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 26 – 30, 2017

1 October 2017
This site is registered on as a development site.